Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: A randomized, controlled trial
Publication in refereed journal

Times Cited
Web of Science14WOS source URL (as at 28/11/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractBackground: A phase III, double-blind, randomized, controlled trial was conducted in Hong Kong to evaluate the efficacy, safety and immunogenicity of a human rotavirus vaccine, RIX4414 (Rotarix (TM)) against severe rotavirus gastroenteritis in children up to three years of age.
All Author(s) ListLau YL, Nelson EAS, Poon KH, Chan PKS, Chiu S, Sung R, Leung CW, Ng D, Ma YM, Chan D, Lee TL, Tang J, Kwan YW, Ip P, Ho M, Fung LWE, Tang HW, Suryakiran PV, Han HH, Bock H
Journal nameVaccine
Volume Number31
Issue Number18
Pages2253 - 2259
LanguagesEnglish-United Kingdom
KeywordsEfficacy; Gastroenteritis; Hong Kong; Intussusception; Rotavirus; Safety
Web of Science Subject CategoriesImmunology; IMMUNOLOGY; Medicine, Research & Experimental; MEDICINE, RESEARCH & EXPERIMENTAL; Research & Experimental Medicine

Last updated on 2020-29-11 at 01:54